Eligibility requirements for clinical trials help protect patients whose comorbidities may put them at an additional risk of severe harm from the treatment being tested. Further, they help ensure that analyses are performed on a carefully controlled population, minimizing outliers that could skew the data. However, the patients who will eventually receive the treatment are not homogeneous. New therapies hitting the market have not always been tested in patients with diverse backgrounds and medical histories. A 2015 study found that 39% of patients treated for renal cell carcinoma in clinical Read More